Research Topics
| Andrew N PhillipsSummaryAffiliation: University College London Country: UK Publications
| Collaborators
|
Detail Information
Publications
Increased HIV incidence in men who have sex with men despite high levels of ART-induced viral suppression: analysis of an extensively documented epidemicAndrew N Phillips
Research Department of Infection and Population Health, UCL, London, United Kingdom
PLoS ONE 8:e55312. 2013....- Partners of people on ART - a New Evaluation of the Risks (The PARTNER study): design and methodsAlison Rodger
Research Department of Infection and Population Health, University College London, London, UK
BMC Public Health 12:296. 2012..There are no data on risk of transmission for anal sex in MSM when the index partner is on ART... 
Effect on transmission of HIV-1 resistance of timing of implementation of viral load monitoring to determine switches from first to second-line antiretroviral regimens in resource-limited settingsAndrew N Phillips
Department of Infection and Population Health, UCL, UK
AIDS 25:843-50. 2011..There is concern that antiretroviral therapy (ART) use with only clinical monitoring for failure will result in high rates of transmission of virus with resistance to drugs currently in use...- Ongoing changes in HIV RNA levels during untreated HIV infection: implications for CD4 cell count depletionAndrew N Phillips
HIV Epidemiology and Biostatistics Group, Research Department of Infection and Population Health, Royal Free Campus, UCL Royal Free Campus, London, UK
AIDS 24:1561-7. 2010..Understanding of the interplay between plasma HIV RNA level and CD4 cell count depletion in untreated infection remains incomplete... - Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression?Loveleen K Bansi
Department of Primary Care and Population Sciences, Royal Free and University College Medical School, Hampstead Campus, Rowland Hill Street, London, NW3 2PF, UK
AIDS 22:349-56. 2008..We investigated whether previous treatment interruptions are associated with a raised risk of viral rebound in individuals who have attained virological suppression... 
Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimenAlessandro Cozzi-Lepri
Royal Free and University College Medical School, London, UK
AIDS 21:721-32. 2007..To estimate the extent of drug resistance accumulation in patients kept on a virologically failing regimen and its determinants in the clinical setting...- Stability of antiretroviral regimens in patients with viral suppressionRebecca K Lodwick
Research Department of Infection and Population Health, Division of Population Health, Royal Free and University College Medical School, London, UK
AIDS 22:1039-46. 2008..To study the rate of treatment change due to toxicities in patients who achieved viral suppression within 6 months of starting antiretroviral therapy and who have never experienced virological failure... - Virological rebound after suppression on highly active antiretroviral therapyAmanda Mocroft
Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
AIDS 17:1741-51. 2003..Treatment-naive patients were at a lower risk of rebound, but among drug-experienced patients, those who added new nucleosides had a lower risk of rebound, as were patients with a good immunological response... - Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort studyAlessandro Cozzi-Lepri
Research Department of Infection and Population Health, Royal Free and University College Medical School, London, UK
AIDS 22:2187-98. 2008..To investigate the relationship between detection of HIV drug resistance by 2 years from starting antiretroviral therapy and the subsequent risk of progression to AIDS and death... - Short-term clinical disease progression in HIV-1-positive patients taking combination antiretroviral therapy: the EuroSIDA risk-scoreAmanda Mocroft
Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
AIDS 21:1867-75. 2007..To derive and validate a clinically applicable prognostic score for predicting short-term disease progression in HIV-infected patients taking combination antiretroviral therapy (cART)... - Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremiaAmanda Mocroft
Department of Primary Care and Population Sciences, Royal Free and University College Medical School, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK
AIDS 20:1141-50. 2006..It is unknown if the CD4 cell count response differs according to antiretroviral drugs used in combination antiretroviral therapy (cART) in patients with maximal virological suppression [viral load (VL) < 50 copies/ml]... - Causes of death in HIV infection: the key determinant to define the clinical response to anti-HIV therapyAmanda Mocroft
Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
AIDS 18:2333-7. 2004..Compared with homosexual individuals, IDU had an increased incidence of new AIDS/death, but only for non-HIV deaths. There is an urgent need to define and standardize causes of death in observational studies... - Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patientsAmanda Mocroft
HIV Epidemiology and Biostatistics Group, Research Department of Infection and Population Health, Division of Population Health, University College London Medical School, Royal Free Campus, London, UK
AIDS 24:1667-78. 2010..Chronic kidney disease (CKD) in HIV-positive persons might be caused by both HIV and traditional or non-HIV-related factors. Our objective was to investigate long-term exposure to specific antiretroviral drugs and CKD... - Risk of discontinuation of nevirapine due to toxicities in antiretroviral-naive and -experienced HIV-infected patients with high and low CD4+ T-cell countsAmanda Mocroft
Royal Free and University College Medical School, London, UK
Antivir Ther 12:325-33. 2007.... - Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort studyAndrew N Phillips
Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
Lancet 370:1923-8. 2007..We estimated the proportion of patients who had extensive triple-class failure during long-term follow-up and examined characteristics associated with an increased rate of failure... - Estimated average annual rate of change of CD4(+) T-cell counts in patients on combination antiretroviral therapyAmanda Mocroft
Research Department of Infection and Population Health, University College London Medical School, London, UK
Antivir Ther 15:563-70. 2010..Patients receiving combination antiretroviral therapy (cART) might continue treatment with a virologically failing regimen. We sought to identify annual change in CD4(+) T-cell count according to levels of viraemia in patients on cART... - HIV-1 subtypes and response to combination antiretroviral therapy in EuropeWendy P Bannister
Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
Antivir Ther 11:707-15. 2006..Antiretroviral drugs have predominantly been developed in Western Europe/North America on the basis of the most prevalent subtype, B. However, non-B subtypes are increasingly spreading worldwide... - Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational studyRebecca K Lodwick
HIV Epidemiology and Biostatistics Group, Research Department of Infection and Population Health, UCL Medical School, Royal Free Campus, London, UK
Lancet 376:340-5. 2010..We aimed to examine this by analysis of pooled data from industrialised countries... - Are specific antiretrovirals associated with an increased risk of discontinuation due to toxicities or patient/physician choice in patients with hepatitis C virus coinfection?Amanda Mocroft
Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
Antivir Ther 10:779-90. 2005..Little information to address this concern is available from clinical trials as patients with HCV are often excluded... - Discordant responses on starting highly active antiretroviral therapy: suboptimal CD4 increases despite early viral suppression in the UK Collaborative HIV Cohort (UK CHIC) StudyR J C Gilson
Centre for Sexual Health and HIV Research, Research Department of Infection and Population Health, University College London, The Mortimer Market Centre, Camden Primary Care Trust, London, UK
HIV Med 11:152-60. 2010..This study was designed to determine the incidence of a discordant response at two time-points, soon after 6 months and at 12 months, and to determine the relationship with clinical outcomes... - Outcomes in the first year after initiation of first-line HAART among heterosexual men and women in the UK CHIC StudyTristan J Barber
St Stephen s AIDS Trust Clinical Trials Unit, Chelsea and Westminster NHS Foundation Trust, London, UK
Antivir Ther 16:805-14. 2011..We analysed the influence of gender on use and outcomes of first-line HAART in a UK cohort... - Low-frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapyAnna Maria Geretti
Department of Virology, Royal Free Hampstead NHS Trust, London, UK
J Acquir Immune Defic Syndr 52:569-73. 2009..There are conflicting data on the impact of low-frequency transmitted drug-resistant mutants on responses to first-line highly active antiretroviral therapy (HAART)... - Increased duration of viral suppression is associated with lower viral rebound rates in patients with previous treatment failuresAndrew A Benzie
St Mary s Hospital, London, UK
AIDS 21:1423-30. 2007.... - Response to efavirenz-containing regimens in previously antiretroviral-naive HIV-positive patients: the role of genderColette J Smith
HIV Biostatistics and Epidemiology Group and Department of Primary Care and Population Science, Royal Free and University College Medical School, London, United Kingdom
J Acquir Immune Defic Syndr 46:62-7. 2007..We investigated the role of gender on response to efavirenz (EFV)-containing regimens in previously antiretroviral-naive patients... - Rate of viral rebound according to specific drugs in the regimen in 2120 patients with HIV suppressionAndrew N Phillips
Royal Free Centre for HIV Medicine, Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
AIDS 18:1795-804. 2004..CONCLUSION: Viral rebound rates in patients who have attained < 50 copies/ml appear to differ according to the specific drugs being used... - Effect of transient antiretroviral treatment during acute HIV infection: comparison of the Quest trial results with CASCADE natural history studyFiona C Lampe
Royal Free Centre for HIV Medicine, Royal Free and University College Medical School, London, UK
Antivir Ther 12:189-93. 2007..6 years, and 17.7% (95% confidence interval [CI]: 10.9-27.6) fulfilled the primary endpoint of VL < or =1,000 copies/ml 24 weeks after CART discontinuation... - Late diagnosis in the HAART era: proposed common definitions and associations with mortalityCaroline A Sabin
Research Department of Infection and Population Health, UCL Medical School, London, UK
AIDS 24:723-7. 2010.... - Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell countAndrew N Phillips
Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
AIDS 21:1717-21. 2007..To assess the absolute rate of AIDS and death in antiretroviral therapy (ART)-naive patients with a high CD4 cell count. Such information would be helpful in the design of a trial investigating early initiation of ART... - Haemoglobin and anaemia in the SMART studyAmanda Mocroft
University College Medical School, London, UK
Antivir Ther 16:329-37. 2011..Data from randomized trials on the development of anaemia after interruption of therapy are not well-described... - CD4 counts and the risk of systemic non-Hodgkin's lymphoma in individuals with HIV in the UKMark Bower
Research Department of Infection and Population Health, Division of Population Health, UCL Medical School, Royal Free Campus, Rowland Hill Street, London, NW3 2PF, UK
Haematologica 94:875-80. 2009..Earlier highly active anti-retroviral therapy initiation and wider access to HIV testing is advocated to reduce the risk of systemic non-Hodgkin's lymphoma... - Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapyColette J Smith
Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, Royal Free Campus, London, United Kingdom
J Infect Dis 190:1860-8. 2004..We sought to investigate the factors associated with increases in CD4 cell count among human immunodeficiency virus (HIV)-positive antiretroviral-naive patients starting HAART... - Deaths in the era of HAART: contribution of late presentation, treatment exposure, resistance and abnormal laboratory markersCaroline A Sabin
Department of Primary Care and Population Sciences, Royal Free and UC Medical School, Pond St, London, UK
AIDS 20:67-71. 2006..To describe the characteristics of deaths that occur among HIV-positive individuals in the HAART era... - Thymidine analogue mutation profiles: factors associated with acquiring specific profiles and their impact on the virological response to therapyAlessandro Cozzi-Lepri
Royal Free and University College Medical School, London, UK
Antivir Ther 10:791-802. 2005.... - Antiretroviral drug resistance in HIV-1-infected patients with low-level viremiaNicola E Mackie
Imperial College Healthcare National Health Service Trust, London, United Kingdom
J Infect Dis 201:1303-7. 2010..7%] of 7861 tests). We conclude that HIV-1 genotypic resistance testing is informative for patients with low viral loads... - Viral breakthrough after suppression with highly active antiretroviral therapy: experience from 233 individuals with viral loads of less than 50 copies/ml followed for up to 4 yearsFiona C Lampe
Royal Free Centre for HIV Medicine, London, UK
AIDS 17:768-70. 2003 - The potential for CD4 cell increases in HIV-positive individuals who control viraemia with highly active antiretroviral therapyColette J Smith
Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, Royal Free Campus, London, UK
AIDS 17:963-9. 2003..To study the long-term CD4 cell responses to highly active antiretroviral therapy (HAART) in treatment-naive patients whose viral loads remained below 500 copies/ml for prolonged periods... - Late presenters in the era of highly active antiretroviral therapy: uptake of and responses to antiretroviral therapyCaroline A Sabin
Royal Free and University College Medical School, Royal Free NHS Trust, London, UK
AIDS 18:2145-51. 2004..To investigate the characteristics and clinical, immunological and virological outcomes for individuals presenting for care with low CD4 cell counts... - Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settingsAlessandro Cozzi-Lepri
Research Department of Infection and Population Health, Royal Free and University College Medical School, London, United Kingdom
J Infect Dis 200:687-97. 2009.... - Can linear regression modeling help clinicians in the interpretation of genotypic resistance data? An application to derive a lopinavir-scoreAlessandro Cozzi-Lepri
Department of Infection and Population Health, Division of Population Health, UCL Medical School, Royal Free Campus, London, United Kingdom
PLoS ONE 6:e25665. 2011.... - Is there evidence for an increase in the death rate from liver-related disease in patients with HIV?Amanda Mocroft
Royal Free Centre for HIV Medicine and Dept Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
AIDS 19:2117-25. 2005..Increases in deaths due to liver-related disease (LRD) among HIV-infected individuals have been reported although the influence of combination antiretroviral therapy (cART) on LRD is controversial... - Limited but increasing use of treatment for hepatitis C across Europe in patients coinfected with HIV and hepatitis CAmanda Mocroft
Royal Free Centre for HIV Medicine, Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
Scand J Infect Dis 38:1092-7. 2006..6 - 6.1) to 32.6 per 1000 PYFU at/after 2004 (95% CI 22.5 - 42.7). Although prescription of HCV therapy is increasing in HIV-coinfected patients, it remains infrequent and variable across regions of Europe... - CD4 cell count changes in individuals with counts above 500 cells/mm and viral loads below 50 copies/ml on antiretroviral therapyAndrew N Phillips
Royal Free Centre for HIV Medicine, London, UK
AIDS 16:1073-5. 2002 - Changes in viral load in people with virological failure who remain on the same HAART regimenAlessandro Cozzi-Lepri
Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, Royal Free Campus, London, UK
Antivir Ther 8:127-36. 2003..The time-course of selecting more replication-competent virus in patients with virological failure remains to be fully clarified... - Projected life expectancy of people with HIV according to timing of diagnosisFumiyo Nakagawa
HIV Epidemiology and Biostatistics Group, Research Department of Infection and Population Health, University College London, UK
AIDS 26:335-43. 2012..Our aims were to estimate the life expectancy of an HIV-infected MSM living in a developed country with extensive access to ART and healthcare, and to assess the effect of late diagnosis on life expectancy... - Decline in esophageal candidiasis and use of antimycotics in European patients with HIVAmanda Mocroft
Royal Free Centre for HIV Medicine and Dept Primary Care and Population Sciences, Royal Free and University College Medical School, London, United Kingdom
Am J Gastroenterol 100:1446-54. 2005..CONCLUSIONS: There has been a marked decline in the incidence of EC between 1994 and 2004. This was accompanied by a decline in markers associated with fungal disease, including use of antimycotics and a decline in duration of treatment... - HIV-associated central nervous system diseases in the recent combination antiretroviral therapy eraLucy Garvey
Clinical Trials Centre, Winston Churchill Wing, St Mary s Hospital, London, W2 1NY, UK
Eur J Neurol 18:527-34. 2011..Data describing the incidence and survival of HIV-related central nervous system diseases (CNS-D) in recent years are sparse... - The relationship between CD4 cell count nadirs and the toxicity profiles of antiretroviral regimensJ Smith Colette
Centre for HIV Medicine, Department of Primary Care and Population Sciences, Royal Free and University College Medical School, Royal Free Hospital, London, UK
Antivir Ther 10:459-67. 2005..We investigated the relationship between the pre-HAART CD4 count nadir, HAART and the occurrence of laboratory-defined toxicities... - Regional changes over time in initial virologic response rates to combination antiretroviral therapy across EuropeWendy P Bannister
Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
J Acquir Immune Defic Syndr 42:229-37. 2006..Regional variations may identify differences in available antiretroviral drugs or patient management... - Long-term trends in adherence to antiretroviral therapy from start of HAARTValentina Cambiano
HIV Epidemiology and Biostatistics Group, Research Department of Infection and Population Health, UCL Medical School, Royal Free Campus, London, UK
AIDS 24:1153-62. 2010..We aimed to investigate long-term trends in highly active antiretroviral therapy (HAART) adherence to identify the main predictors and to evaluate whether participants experience periods of low adherence (<or=60%)... - Cost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoringViktor von Wyl
Research Department of Infection and Population Health, University College London, London, United Kingdom
PLoS ONE 7:e42834. 2012..We conducted a cost-effectiveness analysis with emphasis on emerging patterns of drug resistance upon treatment failure and their impact on second-line therapy... - Markers of HIV-1 disease progression in individuals with haemophilia coinfected with hepatitis C virus: a longitudinal studyCaroline A Sabin
Department of Primary Care and Population Sciences, Royal Free Centre for HIV Medicine, Royal Free and University College Medical School, London, UK
Lancet 360:1546-51. 2002..We aimed to assess the relation between markers of liver function and progression to AIDS and death in individuals with haemophilia infected with HIV-1 and hepatitis C virus... - The changing pattern of Kaposi sarcoma in patients with HIV, 1994-2003: the EuroSIDA StudyAmanda Mocroft
Royal Free Centre for HIV Medicine, Royal Free and University College Medical School, London, United Kingdom
Cancer 100:2644-54. 2004..There continues to be an increased incidence of KS among homosexual men and a greatly reduced incidence of KS among patients with higher CD4 counts... - Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infectionSabine Kinloch-de Loes
Department of Medicine, Royal Free Centre for HIV Medicine, Royal Free and University College Medical School, London, United Kingdom
J Infect Dis 192:607-17. 2005..Our trial design appears to be feasible and safe for testing future immune-boosting strategies... - Transmitted drug resistant HIV-1 and association with virologic and CD4 cell count response to combination antiretroviral therapy in the EuroSIDA StudyWendy P Bannister
Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, United Kingdom
J Acquir Immune Defic Syndr 48:324-33. 2008..To investigate prevalence of transmitted drug-resistant human immunodeficiency virus (TDR) and factors associated with TDR and to compare virological and CD4 count response to combination antiretroviral therapy... - The rate of viral rebound after attainment of an HIV load <50 copies/mL according to specific antiretroviral drugs in use: results from a multicenter cohort studyColette J Smith
Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, United Kingdom
J Infect Dis 192:1387-97. 2005.... - Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trialAndrew N Phillips
Department of Primary Care and Population Sciences, Royal Free University College Medical School, London, UK
Antivir Ther 13:177-87. 2008..Exploratory analyses were performed to better understand the reasons for this observation... - Use of viral load measured after 4 weeks of highly active antiretroviral therapy to predict virologic outcome at 24 weeks for HIV-1-positive individualsColette J Smith
Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, Royal Free Campus, London, United Kingdom
J Acquir Immune Defic Syndr 37:1155-9. 2004..We suggest that this group of patients should be particularly closely monitored... - Physical and psychological symptoms and risk of virologic rebound among patients with virologic suppression on antiretroviral therapyFiona C Lampe
Department of Infection and Population Health, University College London Medical School, London, UK
J Acquir Immune Defic Syndr 54:500-5. 2010..We examined the association of self-reported physical and psychological symptoms with subsequent virologic rebound among patients with viral suppression on combination antiretroviral therapy (cART)... - Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation modelAndrew N Phillips
HIV Epidemiology and Biostatistics Group, Department of Primary Care and Population Sciences, and Royal Free Centre for HIV Medicine, Royal Free and University College Medical School, University College London, London, UK
Lancet 371:1443-51. 2008..Our aim was to study the potential consequences of such monitoring strategies, especially in terms of survival and resistance development... - The associations between age and the development of laboratory abnormalities and treatment discontinuation for reasons other than virological failure in the first year of highly active antiretroviral therapyC A Sabin
Department of Primary Care and Population Science, Royal Free and UC Medical School, London, UK
HIV Med 10:35-43. 2009.... - Virologic, immunologic, and clinical response to highly active antiretroviral therapy: the gender issue revisitedAntonia L Moore
Department of Primary Care and Population Sciences, Royal free and University College School fo Medicine, Hampstead, London, UK
J Acquir Immune Defic Syndr 32:452-61. 2003..Highly active antiretroviral therapy (HAART) has dramatically improved the prognosis for patients with HIV. There is ongoing debate over a potential gender effect on patient outcome after HAART... - Plasma HIV-1 RNA detection below 50 copies/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapyTomas Doyle
Department of Virology, Royal Free Hampstead NHS Trust, and Department of Virology, UCL Medical School, London, United Kingdom
Clin Infect Dis 54:724-32. 2012..Current viral load (VL) assays show increased sensitivity, but the significance of RNA detection <50 copies/mL is unclear... - HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South AfricaJeffrey W Eaton
Department of Infectious Disease Epidemiology, Imperial College London, London, United Kingdom
PLoS Med 9:e1001245. 2012..This study compares the predictions of several mathematical models simulating the same ART intervention programmes to determine the extent to which models agree about the epidemiological impact of expanded ART... - Gender and clinical outcomes after starting highly active antiretroviral treatment: a cohort studyAntonia L Moore
Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, Hampstead, London, UK
J Acquir Immune Defic Syndr 29:197-202. 2002..To examine gender differences in clinical response to highly active antiretroviral treatment (HAART)... - Should HIV therapy be started at a CD4 cell count above 350 cells/microl in asymptomatic HIV-1-infected patients?Caroline A Sabin
Research Department of Infection and Population Health, Division of Population Health, UCL Medical School, University College London, Royal Free Campus, Rowland Hill Street, London, UK
Curr Opin Infect Dis 22:191-7. 2009..The aim is to review the available data that contribute to the debate on the optimal time to initiate highly active antiretroviral therapy (HAART) in HIV-infected individuals with a CD4 cell count more than 350 cells/microl... - Changes in lipids and lipoprotein particle concentrations after interruption of antiretroviral therapyFiona C Lampe
Research Department of Infection and Population Health, University College London, London, United Kingdom
J Acquir Immune Defic Syndr 54:275-84. 2010..We examined short-term changes in lipids and lipoprotein particles among 332 HIV-infected individuals randomized to interrupt or continue ART in the "Strategies for Management of Antiretroviral Therapy" trial... - 'Test-and-treat': the end of the HIV epidemic?Valentina Cambiano
HIV Epidemiology and Biostatistics Group, Research Department of Infection and Population Health, UCL Medical School, London, UK
Curr Opin Infect Dis 24:19-26. 2011..Antiretroviral therapy (ART) has been shown to dramatically reduce viral load which is strongly associated with the risk of transmission, therefore there is the potential to reduce HIV transmissions with ART... - Raised viral load in patients with viral suppression on highly active antiretroviral therapy: transient increase or treatment failure?Antonia L Moore
Department of Primary Care and Population Sciences and Centre for HIV Medicine, Royal Free and University College School of Medicine, Hampstead, London NW3 2PF, UK
AIDS 16:615-8. 2002.... - Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naive Antiretrovirals (I.Co.N.A.) studyAlessandro Cozzi-Lepri
Royal Free Centre for HIV Medicine, Department of Primary Care and Population Sciences, Royal Free and University College Medical School, Rowland Hill Street, London NW3 2PF, UK
J Infect Dis 185:1062-9. 2002..The findings of this study are in agreement with those of other observational studies... - A comparison between abacavir and efavirenz as the third drug used in combination with a background therapy regimen of 2 nucleoside reverse-transcriptase inhibitors in patients with initially suppressed viral loadsAlessandro Cozzi-Lepri
Department of Primary Care and Population Sciences, Royal Free and University College Medical School, University College London, United Kingdom
J Infect Dis 194:20-8. 2006.... - Human immunodeficiency virus rebound after suppression to <400 copies/mL during initial highly active antiretroviral therapy regimens, according to prior nucleoside experience and duration of suppressionAndrew N Phillips
Royal Free Centre for HIV Medicine, Royal Free and University College Medical School, Rowland Hill Street, London NW3 2PF, United Kingdom
J Infect Dis 186:1086-91. 2002..95; P=.009). It appears that only a small period of pre-HAART nucleoside therapy is sufficient to confer a disadvantage, in terms of risk of virus rebound, that persists for several years... - Theoretical rationale for the use of sequential single-drug antiretroviral therapy for treatment of HIV infectionAndrew N Phillips
Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, Rowland Hill Street, London NW3 2PF, UK
AIDS 17:1009-16. 2003..We aimed to explore the use of sequential monotherapy regimens using a mathematical model of quasi-species dynamics, to see if these could take advantage of the poor replicative capacity of highly resistant virus... - Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort studyCaroline A Sabin
Department of Primary Care and Population Sciences, Royal Free and UC Medical School, London NW3 2PF
BMJ 330:695. 2005.... - Success of clinical care for human immunodeficiency virus infection according to demographic group among sexually infected patients in a routine clinic population, 1999 to 2004Fiona C Lampe
Department of Primary Care and Population Sciences, Royal Free and University College Medical School, Royal Free Hospital, Rowland Hill Street, London, England
Arch Intern Med 167:692-700. 2007..The success of clinical care for human immunodeficiency virus infection may vary across demographic groups, because of patient- and health care-related factors... - Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count>or=300 cells/microL who were assigned to 7.5 MIU interleukin-2Zoe Fox
Hvidovre University Hospital, DK 2650 Hvidovre, Denmark
HIV Med 8:112-23. 2007..The IL-2 induction phase consists of three dosing cycles over 6-8 months (7.5 MIU twice a day, for 5 days every 8 weeks)... - The ability of four genotypic interpretation systems to predict virological response to ritonavir-boosted protease inhibitorsZoe V Fox
Copenhagen HIV Programme, Medical Faculty at University of Copenhagen, Denmark
AIDS 21:2033-42. 2007..We compared PI/r resistance levels ascribed by four GIS and examined their abilities to predict HIV-RNA reductions after starting a PI/r-based regimen (baseline)... - Twenty five years of HIV infection in haemophilic men in Britain: an observational studyCaroline A Sabin
Department of Primary Care and Population Sciences, Royal Free and UC Medical School, London NW3 2PF
BMJ 331:997-8. 2005 - Changes over time in risk of initial virological failure of combination antiretroviral therapy: a multicohort analysis, 1996 to 2002Fiona C Lampe
Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, England
Arch Intern Med 166:521-8. 2006..We examined risk of initial virological failure of CART according to the year of starting therapy... - When should antiretroviral therapy for HIV be started?Andrew N Phillips
Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London NW3 2PF
BMJ 334:76-8. 2007 - Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infectionAlison J Rodger
HIV Epidemiology and Biostatistics Group, Research Dept of Infection and Population Health, UCL Medical School, University College London, London, UK
J Infect Dis 200:973-83. 2009..Their associations with opportunistic disease (OD) in human immunodeficiency virus (HIV)-positive patients were examined... - Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort studyGail V Matthews
Department of HIV Medicine, Chelsea Hospital, London, UK
AIDS 16:53-61. 2002..Clinical trial data is required to confirm these findings... - Modelling the impact of treatment with individual antiretroviralsValentina Cambiano
HIV Epidemiology and Biostatistics Group, Research Department of Infection and Population Health, UCL Medical School, London, UK
Curr Opin HIV AIDS 6:124-30. 2011..The focus of our attention is models which explicitly model specific effects of individual antiretroviral drugs...